Biotech Premarket Movers: Spectrum, BioCryst, Curis

Shares of Spectrum Pharmaceuticals (SPPI) were down 12% to $5.50 in premarket trading on Thursday. The Henderson, Nev.-based company, which focuses on hematology and oncology, after the market close on Wednesday reported a fourth-quarter net loss of $17.4 million, or 22 cents per basic and diluted share, compared with a net loss of $4.2 million, or 6 cents per basic and diluted share in the year-ago period. Revenue was $35.2 million, compared to $50.3 million in the same period in 2015.

BioCryst Pharmaceuticals (BCRX) shares were down 4.9% to $8. The Research Triangle Park, N.C.-based company on Wednesday said it is offering to sell $45 million of its common stock in an underwritten public offering. BioCryst, which focuses on treatments for rare and infectious diseases, said it plans to give the underwriters a 30-day option to buy up to an additional $6.75 million of its common stock.

Among the other stock movers is Curis (CRIS) , whose shares rose nearly 2% to $2.60. The Lexington, Mass.-based firm, which focuses on cancer treatment, on Thursday reported a fourth-quarter net loss of $11.3 million or 8 cents per share on both basic and diluted basis, compared with a net loss of $13.5 million, or 10 cents per share on both basic and diluted basis in the same period in 2015. Revenue for the quarter was $2.4 million, compared with $2.1 million in the year-ago period.

Also on Thursday, Curis announced that on March 6 it inked an agreement with HealthCare Royalty Partners for a $45 million debt transaction secured with future Erivedge royalties. Erivedge was developed and is marketed by Roche and its Genentech unit under a collaboration agreement between Curis and Genentech.

If you liked this article you might like

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting